Distribution Solutions Group filed its preliminary proxy and a companion Schedule 13E-3 on September 1, for a merger agreement dated July 15. LKCM Headwater — Luther King Capital's private arm, already the controlling holder, with a founding member on the board — is buying the rest at USD 35.00 in cash. The background section is better than most. LKCM opened at USD 29.50 on March 14; the special committee countered at USD 39.50; LKCM came back with USD 31.00 on May 6, which the committee rejected; the committee then put USD 35.00 on the table on June 18 and called it best and final. LKCM paid it. Controllers do not usually bid against themselves, and this one raised its own opening bid by USD 5.50 to a number it did not pick.

Why now?

The proxy is two days old, the record and meeting dates are still empty brackets, and the gross spread at Tuesday's close of USD 34.66 is about 1%. There is no trade here. What is new is the disclosure — William Blair's analyses, management's projections and the Section 144 machinery landed at once, and they do not point the same direction.

Numbers

• The premium is about the starting point, not the price. USD 35.00 is an 81% premium to the USD 19.31 close on March 13, the last trading day before the proposal. But William Blair's own table puts the deal at 13.5x LTM adjusted EBITDA against a selected-peer median of 15.8x, and 11.5x calendar 2026 estimated EBITDA against a peer median of 14.4x. The stock was cheap. The offer is not rich.

• Management's forecast runs USD 23 million ahead of the Street in the year the deal is priced off. Blair used CY2026 estimated adjusted EBITDA of USD 203 million from company projections and USD 180 million from consensus. Those same projections feed the buyer's return math.

• That return math survives comfortably here. Blair's leveraged buyout analysis produces USD 26.61 to USD 37.00 per share at an 18% to 22% IRR, on 2030 adjusted EBITDA of USD 357 million against USD 173 million LTM. The discounted cash flow range is USD 24.86 to USD 42.63. USD 35.00 sits inside both and at the top of neither.

Risks — what kills it

At a 1% spread there is no cushion, and there is no go-shop — the word does not appear in the proxy. Closing is conditioned on a Disinterested Stockholder Approval under Section 144 of the DGCL, which excludes the affiliated holders, the non-committee directors and the company's officers. If enough minority holders read the multiple table the way I just did, the vote stalls and the stock goes back toward a price with a one in front of it. Net debt was USD 920 million at March 31, roughly 5.3x LTM adjusted EBITDA, before the buyout adds more.

What to monitor

• The definitive proxy filling in the record and meeting dates.

• ISS and Glass Lewis, who have a live multiple argument to work with.

• Any unaffiliated holder filing a 13D or a public objection.

• The affiliated ownership percentage, still "approximately %" in the preliminary.

• The credit facility amendment permitting the buyout borrowing.

Sources

• DSGR PREM14A (9/1/26) — every figure above except the market price.

• DSGR SC 13E-3 (9/1/26)

• DSGR EDGAR filing history

• stockanalysis — DSGR — the USD 34.66 close, September 2, 2026.

If you cover industrial distribution or controlling-stockholder take-privates professionally and have a sharper read, the reader form routes straight to the editor. The best pushback reshapes what gets written next.

Limbach spent two years being repriced as a data-centre-adjacent growth story and then repriced back. It closed at USD 48.58 on September 2 against a 52-week high of USD 114.95 — down roughly 58%. Yaron Naymark of 1 Main Capital laid out the setup on Andrew Walker’s Yet Another Value Podcast on September 1, framing it as a company that missed the boom and asking whether that is the opportunity. The filings say the pivot itself is real, and that its economics got worse this year — which is a more interesting thing to argue about than the share price.

Why now?

On September 1 Limbach filed an 8-K announcing it had closed the acquisition of 1901 Inc., a Madison, Wisconsin mechanical contractor, for an initial USD 63.0 million at closing plus up to USD 6.0 million of performance earnouts payable over two years. It is paying with cash on hand and borrowings under a revolver it expanded from USD 100 million to USD 125 million on July 24 — five weeks earlier. The company held USD 17.5 million of cash at June 30, so most of that 63 is borrowed. The stock rose 8.7% on the day.

The numbers

• Growth without profit. Second-quarter revenue was USD 173.5 million against USD 142.2 million, up 21.9%. Gross profit was USD 37.3 million against USD 39.8 million, down 6.4%. Gross margin went 28.0% to 21.5%. Across six months, revenue is up 13.4% and gross profit is down 10.6%.

• It happened in the segment that is supposed to be the good one. Owner Direct Relationships revenue rose to USD 128.4 million from USD 108.9 million, up 17.9%, while ODR gross profit fell to USD 30.8 million from USD 31.6 million. Owner-direct is the higher-margin business the entire pivot was built to grow.

• What it costs and what it owes. 11,924,993 shares at the August 3 cover count, times 48.58, is about USD 579 million. Against USD 17.5 million of cash and USD 40.7 million of total debt at June 30 — before the 1901 draw. Net income was USD 4.7 million in the quarter against USD 7.8 million, and USD 9.1 million across six months against USD 18.0 million.

What kills it

That the margin compression is structural rather than mix. If owner-direct work is being won on price, or acquired revenue simply carries worse economics than the legacy book, then the reason to own this is gone and 58% off the high is not automatically enough. Second, leverage: adding USD 63 million of mostly-borrowed purchase price while gross profit falls leaves less room than the June 30 balance sheet suggests. Third, this is a labour business in a cyclical end market, and the market has already re-rated the growth story once this year.

What to monitor

• Third-quarter gross margin — whether it stabilises near 21–22% or keeps sliding.

• ODR gross profit in dollars, not ODR revenue. That is the line that actually broke.

• The drawn revolver balance and the senior leverage ratio once 1901 is consolidated.

• Whether the USD 6.0 million earnout gets earned, which would say something about what was bought.

• Any further acquisitions announced before the margin question is answered.

Sources

• Yet Another Value Podcast — “LMB: Limbach missed the data center boom. Is that the opportunity?” with 1 Main Capital, September 1, 2026 — the idea and the framing

• Limbach 8-K, September 1, 2026 — the 1901 Inc. closing, the USD 63.0 million initial price, the USD 6.0 million earnouts, the cash-and-revolver funding

• Limbach 8-K, July 24, 2026 — the Third Amendment raising the revolver from USD 100 million to USD 125 million

• Limbach 10-Q for the quarter ended June 30, 2026 — revenue, gross profit and net income by period, the ODR and GCR segment split, cash, debt and the 11,924,993 share cover count

• stockanalysis — LMB — USD 48.58 close and the 52-week range, September 2, 2026

Last time out: UTZ — the family gets 44 million on the side, and puts 33 of it straight back in. Tomorrow at 7 AM ET, a new one. Full archive →

On August 24 Utz Brands filed a preliminary proxy and a companion SC 13E-3 for a merger with Intersnack Group GmbH & Co. KG, the German snack group. Class A holders get USD 14.25 in cash, a premium of approximately 91% to the July 20, 2026 close. That number is doing a lot of work. The proxy’s own price table shows Class A as high as USD 20.04 in the second quarter of 2024 and as low as USD 6.78 in the second quarter of 2026. A 91% premium on a stock that had already lost two-thirds of its value is not the same object as a rich price.

Why now?

The proxy is preliminary: the record and meeting dates are still bracketed placeholders and the third-quarter price table is blank. Nobody has voted. What is filed is the plumbing — the merger, a separate TRA Payment and a Recapitalization together “constitute a ‘going private transaction’” in the filer’s own words, three moving parts where a normal take-private has one.

The numbers

• The side payment, and where it lands. At closing the surviving corporation pays the Continuing Stockholders an aggregate USD 44,000,000 to terminate the tax receivable agreement — USD 38,193,538 to Series U, USD 5,806,462 to Series R. Concurrently those same holders buy 2,315,790 common units at USD 14.25 each, or USD 33,000,007.50, and the proxy notes those amounts “may be net settled against the TRA Payment.”

• The price is not the scandal. Citi’s analyses for the special committee implied USD 5.70–9.00 on trading comps, USD 10.15–13.15 on precedent transactions and USD 10.60–14.80 on the DCF. USD 14.25 sits above two of those ranges entirely and near the top of the third. The “illustrative” USD 15.00–17.00 figures elsewhere in the background section are premium arithmetic off a December 2025 price, not a valuation.

• Who sits on which side. The Continuing Stockholders hold 4.74% of Class A and 38.45% of the operating-company units; family holders together control roughly 42% of the voting power. Every Class V share — voting, no economics — is cancelled for no consideration. Book value ex-minority interest was USD 7.86 per share at June 28, 2026.

What kills it

Mostly that there is nothing much wrong with it. At USD 14.20 the gross spread is 0.35%, so there is no trade. The special committee held only directors found disinterested under Section 144, Citi opined to the unaffiliated holders, and approval needs both a majority of shares outstanding and a majority of votes cast by disinterested stockholders — more minority protection than most controller deals carry, and plainly engineered to land inside Delaware’s amended safe harbor. The counterweight: any alternative was structurally foreclosed, since the investor rights agreement barred certain change-of-control transactions without the family’s consent, and the family has since signed a voting agreement.

What to monitor

• The definitive proxy, and the record and meeting dates it fills in.

• Whether the disinterested-stockholder vote draws organized opposition — abstentions do not count against that standard, only votes cast.

• Appraisal chatter under Section 262, the only other remedy on offer.

• Whether anyone tests the Section 144 safe harbor in Chancery on this fact pattern.

• The USD 50,000,000 termination fee, if a topping bid ever materialises.

Sources

• Utz Brands PREM14A, August 24, 2026 — consideration, premium, TRA Payment and allocation, unit purchase and net-settlement, Citi’s ranges, Class V cancellation, book value, ownership, voting standards, termination fee

• Utz Brands EDGAR filing history — PREM14A and SC 13E-3, both August 24, 2026

• stockanalysis — UTZ — USD 14.20 close, August 31, 2026

Built from public filings and existing write-ups in roughly the time it takes a reader to finish their first coffee. If the math, the framing, or the timing is wrong, that’s the most useful kind of reply.

Curium agreed on August 3 to buy Lantheus for USD 102.50 a share in cash plus one non-transferable contingent value right worth up to USD 12.00, a headline ceiling of USD 114.50. The preliminary proxy filed August 26 is unusually generous about what that strip is. It annexes the form of CVR agreement, spells out all eight milestones with thresholds and measurement years, and — rarely for a deal proxy — prints management’s own adjusted-sales projections for the three franchises those milestones are measured against. The arithmetic the board already did is right there.

Why now?

The proxy is a week old, the record date is still an empty bracket, and there is no meeting date to handicap. The stock closed Monday at USD 100.96 — 1.5% below the cash consideration alone. The market is not marking the CVR down; it is paying less than nothing for a strip whose terms are now fully on file.

Numbers

• Prostate is where the money is, and it is projected to miss. Management forecasts the Global Prostate Cancer Diagnostics Franchise at USD 991 million of adjusted sales in 2030. The first milestone needs USD 950 million in that one calendar year — cleared by 4.3%. The four larger tranches behind it, worth USD 7.00 of the USD 12.00, need USD 1.10 billion to USD 1.75 billion and are not projected to be earned. Note the shape: the franchise peaks at USD 1,046 million in 2028 and declines into the only year that counts.

• The other two clear, one of them barely. Neurology is projected at USD 351 million in 2029, clearing both the USD 300 million and USD 350 million thresholds for USD 3.00. DEFINITY is projected at USD 408 million in 2030 against a USD 400 million threshold — 2.0% of headroom, worth USD 1.00.

• That totals USD 5.00 of the USD 12.00 on management’s own model. Morgan Stanley discounted that stream at 9.8% to USD 3.51 per share, giving a consideration NPV of USD 106.01 against a DCF range of USD 88.10 to USD 118.60 — while using a negative 5% perpetual growth rate for the Pylarify family in its terminal value.

Risks — what kills it

The forecasts were prepared by management, for this deal, and two of the three clearing milestones clear by 4.3% and 2.0%. Thresholds that sit just under a forecast are a reason to distrust the forecast in both directions, not evidence the CVR pays. The CVR is not a security, is not listed, is non-transferable, accrues no interest and expires January 1, 2031 — four and a half years to find out. The cash leg is 1.5% gross against an outside date of May 2, 2027, extendable to November 30, 2027, which is thin for a long regulatory calendar. And remember how the price got here: the initial proposal was USD 92.00 to USD 95.00 a share, and the CVR is what turned that into a USD 114.50 headline.

What to monitor

• The definitive proxy setting the record and meeting dates.

• Whether the executed CVR agreement differs from the Annex B form.

• Quarterly prostate adjusted sales against the 946 → 991 path, especially the PYLARIFY TruVu transition.

• Neurology sales crossing USD 300 million — the earliest milestone that can be hit.

• HSR clearance and any second request.

Sources

• Lantheus PREM14A (8/26/26) — the eight milestones and thresholds, the franchise projections, the USD 3.51 CVR NPV and USD 106.01 consideration NPV, the Morgan Stanley analyses, the termination fees and the outside date.

• Lantheus 8-K announcing the merger (8/3/26)

• Q2 2026 10-Q — 65,272,369 shares outstanding at 8/3/26

• stockanalysis — LNTH

If you cover radiopharmaceuticals or contingent-value-right structures professionally and have a sharper read, the reader form routes straight to the editor. The best pushback reshapes what gets written next.

On March 3 Arbutus and its licensee Genevant settled all global patent litigation with Moderna. Moderna paid the two of them USD 950 million in July, of which Arbutus took USD 178.4 million on July 8. On August 24 the company filed an SC TO-I to hand most of that straight back — a modified Dutch auction for up to USD 230 million of shares in a band of USD 5.00 to USD 5.75, in five-cent increments. Because Arbutus is a British Columbia company listed on Nasdaq, the same document is simultaneously a US tender offer and a Canadian issuer bid circular, which is where the interesting plumbing comes from.

Why now? The offer expires at 5:00 PM New York time on September 29, 2026, and the stock closed Friday at USD 5.07 — 1.4% above the floor of the company's own range, with the ceiling 13.4% higher. The market is either betting the auction clears at the bottom, or it is not paying much attention to a company whose largest asset is a court docket.

Numbers

• At USD 5.00 the offer takes up to 46,000,000 shares; at USD 5.75, 40,000,000. Against 197,847,835 shares outstanding at August 10, that is 23.3% to 20.2% of the company retired in one transaction — about 23% of the roughly USD 1.0 billion market capitalisation.

• The balance sheet does not obviously support this. Cash, equivalents and marketable securities were USD 92.6 million at June 30 with no debt. The USD 178.4 million landed eight days later, and Arbutus also owns about 16% of Genevant and expects a material dividend from it this quarter.

• What is not being returned: an additional USD 1.3 billion goes to Arbutus and Genevant if an appellate court rules that 28 U.S.C. section 1498 does not bar their claims against Moderna. The company and Genevant also filed suit against Pfizer and BioNTech across 21 countries in July.

What kills it. The appeal is the asset, and appeals lose. If section 1498 stands, the contingent payment is zero and what remains is a clinical-stage biotech with a deliberately shrunken balance sheet. The auction's own mechanics are unfriendly too: Canadian issuer bids permit proportionate tenders, and every one of them mechanically reduces the pool available to ordinary auction tenderers, so nobody can compute their own proration until after the books close. Directors and officers have said they intend to tender up to 682,630 shares at whatever price gets set — insiders taking the certain money. Interesting to dig in on, not a call.

What to monitor

• The section 1498 appeal — any argument date, ruling, or settlement of the contingent piece

• Any SC TO-I/A amending price, size or the expiration before September 29 (none filed as of Friday)

• The size and timing of the Genevant dividend, which is the other half of the funding

• Whether the stock breaks below USD 5.00, the auction's own floor

• Odd-lot holders — under 100 shares — take priority and escape proration entirely

Sources

• Arbutus SC TO-I, tender offer statement and issuer bid circular (8/24/26)

• Offer to Purchase — the band, the September 29 expiration, the share caps, proportionate tenders, odd-lot priority, insider tender intentions

• Q2 2026 results — the Moderna settlement, the USD 178.4 million received July 8, the USD 1.3 billion contingent payment, the Genevant stake (8/12/26)

• Q2 10-Q — cover-page share count (8/12/26)

Last time out: BETR — the founder wants his job back, and he has 22% of the votes he needs. Tomorrow at 7 AM ET, a new one. Full archive →

On August 3 the board, excluding Garg, unanimously voted to transition him out of the chief executive role and appointed director Daniel Lewis interim CEO. Garg said publicly that day that it was the right time for new leadership. Three weeks later he reversed. On August 27 the Garg Group filed a definitive consent statement under DGCL section 228 — no meeting to convene, no annual-meeting date to wait for. Two proposals: restore the bylaws to the form filed with the SEC on August 25, 2023 if the board amends them mid-fight, and remove without cause Lewis, Arnaud Massenet, Bhaskar Menon, Prabhu Narasimhan and Harit Talwar, plus anyone appointed to fill a vacancy on or after August 17. The company filed its own definitive revocation statement the next day. The two sides are now filing against each other daily.

Why now? The clock is short and it is statutory. Consents must be delivered by October 20, 2026 — sixty days from the August 21 record date, the day the earliest consent was delivered — and the Garg Group has set September 8 as its own submission goal. Consents can be revoked until counted, so this is a live tally with a hard stop, not a scheduled vote.

Numbers

• At the August 21 record date there were 13,256,037 Class A shares at one vote each and 4,316,928 Class B shares at three votes each — 26,206,821 votes, with a majority the company itself puts at 13,103,411. Class B is 49.4% of the vote on about a quarter of the equity.

• The Garg Group holds 118,260 Class A and 1,910,964 Class B — 2,029,224 shares, 11.5% of the voting stock, but 5,851,152 consents, or 22.3% of the voting power. He needs roughly another 28 points.

• The stock closed Friday at 13.85, down 5.1% on the day the company’s revocation statement landed, putting the 17.6 million voting shares at about USD 243 million.

What kills it. The gap is the whole problem: he is already the largest supervoting holder and is still 28 points short, soliciting in public against a board mailing revocation cards to the same register. The board’s case is documented and unflattering — the stock is down more than 90% since the de-SPAC closed in August 2023, the company has accumulated more than USD 1.5 billion of net losses since 2022, and the filing catalogues conduct including the termination of roughly 900 employees on a single Zoom call. There is a cost to him winning, too: the company says removing the five would eliminate its chairman, lead independent director, interim CEO and both committee chairs, cutting the audit committee from four members to two and putting Nasdaq listing-rule and Rule 10A-3 compliance in question. Anyone consenting is voting for that outcome as well. Interesting to dig in on, not a call.

What to monitor

• Any 8-K or DEFA14A reporting consents actually delivered — September 8 is the goal, October 20 the statutory stop.

• Whether the board amends the bylaws, the trigger the Bylaw Restoration Proposal is built to catch, or fills vacancies, which the removal proposal pre-empts.

• Who holds the Class B outside the Garg Group — roughly 2.4 million supervoting shares decide this.

• Any Delaware litigation over the consent process or the resulting board.

• Further 13D/A amendments from either side.

Sources

• Garg Group DEFC14A — definitive consent statement, both proposals, the Garg Group holdings, the September 8 goal and the October 20 outside date (8/27/26)

• Better Home & Finance DEFC14A — consent revocation statement, record-date share counts, the 13,103,411 majority, the board’s account of the August 3 transition (8/28/26)

• SEC filing history — Better Home & Finance Holding Company

• stockanalysis — BETR

Built from public filings and existing write-ups in roughly the time it takes a reader to finish their first coffee. If the math, the framing, or the timing is wrong, that’s the most useful kind of reply.

On August 14 MSG Sports filed a Form 10-12B with the Rangers’ information statement attached. MSGS Spinco, Inc. — a Nevada corporation — becomes MSG Rangers Corp., owns the New York Rangers, and lists Class A on the NYSE as MSGR. What stays behind is the Knicks: the parent is renamed MSG Knickerbockers Corp. and takes the symbol MSGK. Holders get one Spinco Class A per two MSGS Class A, expected to qualify as tax-free. So the surviving company is the basketball team and the spinco is the hockey team — worth sitting with, because the half going out the door is the half losing money.

The second thing is that the document is a form with the numbers left out. It contains 114 bracketed [●] placeholders. Record date: [●], 2026. Distribution date: [●], 2026. The Dolan Family Group’s stake — the whole governance question — reads “approximately [●]% of our outstanding Class A Common Stock and approximately [●]% of the total voting power.” Ordinary enough for a first filing. Less ordinary is which decision is already made: the board has elected to be treated as a controlled company and not to comply with the NYSE requirements for a majority-independent board or an independent nominating committee. Nobody knows when this happens. The governance is settled.

Why now? Nothing has been filed since August 14 — no amendment, no date, no timetable. When one arrives, MSGS trades in two markets at once: when-issued before the distribution, regular way after. That seam is where forced selling shows up, and index money that bought a basketball company does not necessarily want a hockey company. Holders are asked for nothing in the meantime — “No stockholder approval of the Distribution is required or sought. We are not asking you for a proxy.”

Numbers

• What is being spun out. The Rangers business did USD 337.3 million of revenue in fiscal 2026 and an operating loss of USD 30.5 million. Fiscal 2025: USD 332.0 million and a USD 23.3 million loss. Fiscal 2024, the last profitable one: USD 401.5 million and USD 26.8 million of operating income.

• The media line has already been cut. Local media rights were USD 35.3 million in fiscal 2026, 10% of revenue, down from USD 39.1 million and 12%. In MSG Networks’ restructuring the Rangers’ telecast fee was reduced 18% effective January 1, 2025, with no escalator, and the term shortened to end after the 2028-29 season.

• The parent, for scale. 24,079,941 shares at July 31, 2026 per the FY2026 10-K cover. At Thursday’s close of USD 393.65 that is about USD 9.5 billion for both teams, against a 52-week range of 193.87 to 438.93.

Risks. MSGS sits near its high, so any sum-of-the-parts argument is being made after the move rather than before it. There is no vote and therefore no deal to break — but equally no date, and a spin with 114 blanks can slip a quarter without anyone breaching anything. The spinco is a loss-making franchise that does not own its building, inside a controlled company whose board has pre-announced it will not be majority-independent. That is a governance discount waiting to be applied, not a catch to be closed.

What to monitor

• An amended Form 10 with the record and distribution dates filled in — the trigger for everything else.

• The Dolan percentages once the brackets are replaced, and whether MSGK is also a controlled company after the split.

• When-issued trading opening, and whether the two lines diverge from the 1-for-2 arithmetic.

• The Tax Matters Agreement restrictions on both sides.

• Anything at all on Rangers local media beyond 2028-29.

Sources

• MSGS Spinco, Inc. — EX-99.1 information statement (filed 8/14/26): Nevada spinco, MSGR/MSGK, 1-for-2 ratio, tax-free treatment, controlled-company opt-out, Rangers financials, local media rights

• Form 10-12B primary document (8/14/26)

• EX-2.1 — Distribution Agreement

• MSGS FY2026 Form 10-K — cover-page share counts at 7/31/26 (filed 8/13/26)

• stockanalysis — MSGS price and 52-week range

If you cover sports franchises or controlled-company spin-offs professionally and have a sharper read, the reader form routes straight to the editor. The best pushback reshapes what gets written next.

On August 18 the Pilgrim’s Pride board received an unsolicited proposal from its majority stockholder, JBS N.V., to buy every PPC share JBS does not already own at a fixed 2.086 JBS Class A shares per PPC share. The 8-K does the arithmetic for you: it cites closing prices that day of USD 13.66 for JBS and USD 28.49 for PPC, and 2.086 × 13.66 is 28.49. A controller offered its minority a zero-percent premium, in writing, on the record. The letter is blunter still: JBS says it has “no interest in a disposition or sale” of its holding and would not vote for any alternative sale or merger. There is no auction here and there cannot be one. What JBS did hand over voluntarily is both MFW prongs up front — an empowered special committee with its own advisers and a veto, plus a condition requiring approval by a majority of the votes cast by shares JBS does not own. Which leaves one question: what is a minority worth when the only permitted buyer has also handed it a veto?

Why now? Ten days on, nothing further has been filed. PPC’s most recent SEC filing of any kind is still the August 20 8-K attaching the letter; the board said it “will be forming” a special committee and has not named one, its members, or its advisers. The market answered anyway — PPC closed Wednesday at USD 31.29 against an implied 2.086 × 13.75 = USD 28.68, roughly 9% through the offer. Everyone is betting the committee makes JBS pay, and nobody has seen who is on it.

Numbers

• The board was built for this. PPC’s description of its securities sets out the JBS Stockholders Agreement: nine directors, six designated by JBS and three “Equity Directors” elected by the other holders, with JBS required to mirror-vote its own shares in proportion to how the minority votes on them. The letter says JBS expects those Equity Directors to approve both the committee’s creation and any deal. Above 90% ownership, JBS elects the whole board.

• What is in dispute. At Wednesday’s close and 238,108,524 shares on the Q2 10-Q cover, PPC is worth about USD 7.4 billion. The roughly 18% JBS does not own is about 43 million shares — about USD 1.3 billion at Wednesday’s price, against about USD 1.2 billion at the offer ratio.

• Both legs are beaten up.JBS Class A closed Wednesday at USD 13.75 against a 52-week high of USD 18.65; PPC’s own high is USD 46.20. An odd moment to fix a ratio permanently.

Risks. JBS can simply walk — the letter says it is non-binding and withdrawable at any time. If it does, the 9% is the first thing to go, and what is left is a chicken company at USD 28-and-change with a controller that has just announced it will never sell. A fixed ratio is not a price, either: whatever happens to JBS shares between now and a closing lands on the minority’s consideration, and there is no collar. The committee may take its independence seriously and still conclude 2.086 is fair. And there is no cash here at all, so it only works if you want to own JBS.

What to monitor

• An 8-K naming the special committee — who is on it, and whether it is the three Equity Directors.

• The committee’s own legal and financial advisers (JBS has Citi and White & Case).

• Any revised ratio, or a JBS withdrawal.

• The ratio against JBS’s price: at 13.75 it is USD 28.68; at 16.00 it is USD 33.38.

• Further amendments from JBS USA Holding Lux, which amended its 13D on August 18.

Sources

• PPC 8-K, Item 8.01 — unsolicited JBS proposal (filed 8/20/26 for an 8/18/26 event)

• Exhibit 99.1 — the JBS proposal letter

• JBS press release, Exhibit 99.2 — JBS currently owns approximately 82% of PPC’s common stock

• PPC description of securities — the JBS Stockholders Agreement and the Equity Directors

Last time out: FMC — a strategic agreed to pay 13.30 for a fifth of the company. Tomorrow at 7 AM ET, a new one. Full archive →

FMC put itself under review in February and, on June 30, announced the answer: no sale, no breakup, a cornerstone equity investment instead. Tessenderlo — Luc Tack's Euronext-listed agro and industrials group — subscribes for 30,319,166 shares at USD 13.30 for USD 403,244,907.80, taking it from under 1% to roughly 20% and completing a rough USD 1 billion debt-paydown target alongside the India business sale, a Corteva licence prepayment, a Newark sale-leaseback and a USD 1.2 billion secured bond. The part nobody quotes is the investor agreement: one independent board seat plus an observer while Tessenderlo holds 10%, a 36-month lockup, top-up rights to stay at 20% — and a standstill that runs for as long as it owns a single share, plus a covenant to vote with the board at every meeting other than a change of control. A 20% holder who cannot buy more, cannot propose a transaction, cannot solicit proxies and cannot vote against management is not an activist. It is a fixed block on the incumbent side of the register.

Why now? The transaction has not closed. It is conditioned on regulatory approvals, and FMC has filed no 8-K since July 29 — so the closing is still ahead, not behind. In the meantime the stock closed Friday at 11.02, seventeen percent below the price a strategic buyer with a data room agreed to pay for a fifth of the business, and within 11% of a 52-week low of 9.95 against a 40.84 high.

Numbers (at the August 21 close):

• 11.02 on 125,226,839 shares (10-Q cover, June 30) is roughly USD 1.38 billion of equity against USD 4,280.6 million of total debt and USD 476.6 million of cash — about USD 3.80 billion net.

• FY26 adjusted EBITDA guidance is USD 620–680 million, cut on July 29. That is just under 6x net leverage now, roughly 5.2x once the USD 403 million lands.

• Because the shares are issued above the market, the placement is accretive, not dilutive: holding enterprise value flat, USD 403 million of debt retired against 30.3 million new shares implies about 11.46 per share versus 11.02 — roughly 4%.

What kills it. The bear case is the one the process itself supplies: a company that ran a full review and produced a minority placement rather than a buyer has told you what control bidders thought it was worth. The business is still deteriorating — Q2 revenue of USD 867 million was down 17%, GAAP net loss was USD 187 million, and full-year adjusted EPS guidance was cut to a 55% decline at the midpoint. Five-plus turns of leverage on a cyclical crop-protection business leaves little room. And the same agreement that makes Tessenderlo patient makes FMC materially harder to take over: a fifth of the vote is pledged to the board for as long as the nominee sits. If the thesis was “someone eventually buys this,” the review just made that less likely, not more. Interesting to dig in on, not a call.

What to monitor

• The closing 8-K and which regulators are gating it — the deal is not done until it is.

• Whether Tessenderlo exercises the top-up right, and who the initial nominee is.

• Q3 revenue excluding India against the lowered USD 3.50–3.70 billion range.

• Free cash flow against the USD 75–225 million guide, which now includes the USD 200 million Corteva prepayment.

• Any 13D from a holder who reads the standstill the way this post does.

Sources

• FMC 8-K — stock purchase agreement, investor agreement, standstill, lockup (7/1/26)

• FMC / Tessenderlo press release — USD 400 million investment, review concluded (6/30/26)

• FMC Q2 2026 results — balance sheet, guidance cut (7/29/26)

• SEC XBRL — FMC cover-page shares outstanding

• stockanalysis — FMC

Built from public filings and existing write-ups in roughly the time it takes a reader to finish their first coffee. If the math, the framing, or the timing is wrong, that's the most useful kind of reply.

Rocket Lab announced the acquisition on June 29 at a USD 54.00 notional. The mechanic that matters showed up six weeks later, in the Form S-4 filed August 13. Each Iridium share gets USD 27.00 cash plus a number of Rocket Lab shares set by a collar: 0.4000 shares if the Rocket Lab Stock Price is at or below USD 67.50, USD 27.00 divided by the price between 67.50 and 112.50, and 0.2400 shares at or above 112.50. "Rocket Lab Stock Price" is defined in the same paragraph as the ten-day VWAP ending on the second full trading day before the merger closes. Not today's price. Not the signing price.

Why now? Iridium closed Friday at 48.98 against a 54.00 notional — call it 10.2% gross — and that number is being quoted as a spread. It isn't one, because the denominator of the exchange ratio is unknowable until closing week. The S-4's own pro forma illustrates the point: it runs the numbers at a ten-day VWAP of USD 69.33 through August 7, producing a ratio of 0.3894. Rocket Lab has since traded to 72.57. Two weeks, two different deals.

Numbers (at the August 21 close):

• Iridium 48.98 on 105,960,383 shares (10-Q cover, July 15) is roughly USD 5.19 billion of equity.

• Rocket Lab at 72.57 is 7.5% above the 67.50 collar floor, and 52% below its own 52-week high of 151.00.

• Below the floor the ratio pins at 0.4000 and Iridium holders own the downside outright. The package is worth today's Iridium price at a Rocket Lab VWAP of about 54.95 — roughly 24% lower.

What kills it. This is not a cash deal with a spread; it is a cash-and-paper deal where holders are effectively short a put on Rocket Lab struck at 67.50 for however many months this takes. The vote standard is a majority of shares outstanding, so abstentions count as no. The proxy is still preliminary — the special meeting date is a bracketed placeholder — and Iridium owes a USD 223,620,000 termination fee in specified circumstances. Rocket Lab is funding the cash with a bridge facility that also has to refinance Iridium's existing credit agreement, which is a financing condition wearing a different hat. Interesting to dig in on, not a call.

What to monitor

• Rocket Lab's price against 67.50 — the only number that changes the deal's character.

• The S-4 going effective and the special meeting date and record date getting filled in.

• Any amendment to the collar or to the cash component.

• Regulatory clearances, including FCC licence transfers, which set the closing date the VWAP window hangs off.

• Whether the bridge facility gets termed out before closing.

Sources

• Rocket Lab Form S-4 — collar, VWAP definition, termination fee, pro forma (8/13/26)

• Rocket Lab 8-K announcing the S-4 and preliminary proxy (8/13/26)

• Rocket Lab deal announcement (6/29/26)

• SEC XBRL — Iridium cover-page shares outstanding

• stockanalysis — IRDM · stockanalysis — RKLB

If you cover satellite communications or collar-structured mergers professionally and have a sharper read, the reader form routes straight to the editor. The best pushback reshapes what gets written next.

On July 29 Churchill Downs filed an 8-K under Item 8.01 saying it "has completed a comprehensive review of the Company's operational portfolio and long-term capital allocation priorities" and "is exploring various options to sell" nine wholly owned regional gaming properties. It names every one: Calder, Terre Haute, Hard Rock Iowa, Oxford, Ocean Downs, Harlow's, Riverwalk, del Lago and Presque Isle Downs. The word "nine" never appears — you count them yourself. What survives if all nine go is the part nobody can replicate: the Kentucky Derby, Churchill Downs Racetrack, the historical-racing-machine estate and TwinSpires.

Why now? The 8-K is deliberately built to give you nothing to trade — no timetable, no bankers, no price, and an explicit line that the Company "does not intend to provide updates unless and until it is determined that disclosure is appropriate or required by law." Which is why the Q2 10-Q filed the same day is the better read. Two things in it change how the 8-K sounds. Long-term debt classified as current went from USD 63 million at March 31 to USD 663 million at June 30. And the buyback that retired roughly 3.8 million shares between February and October 2025 has done essentially nothing in the nine months since. Selling casinos into that is a different sentence than selling casinos from strength.

Numbers (at the August 21 close of USD 93.71):

• About USD 6.5 billion of market value on 69,700,243 shares (Q2 10-Q cover page, July 22), more than 20% below the 52-week high of 118.35.

• Long-term debt of USD 4.77 billion at June 30 — USD 4.11 billion noncurrent plus USD 663 million current — against USD 5.13 billion at year-end. That is real paydown of about USD 357 million; most of the drop in the noncurrent line alone is a reclassification, not a repayment.

• Cover-page shares: 73,548,069 in February 2025, 69,728,742 by October 2025, then 69,700,243 in July 2026. Roughly 3.8 million shares retired in eight months, then 28,499 in nine.

What kills it. The company has pre-announced that there is no catalyst. Regional casino assets are being marketed into a soft consumer and a crowded field of sellers, so "exploring various options" can end in nothing, or at prices that leave the equity no better off. If proceeds go to the USD 663 million and the rest of the stack, this is a creditor event, not an equity one. At USD 6.5 billion it is also a large, well-covered name. Interesting to dig in on, not a call.

What to monitor

• Any 8-K naming a buyer, a price, or a signed agreement on any of the nine.

• The Q3 10-Q cover page: does the share count start falling again?

• How the USD 663 million current maturity gets handled — refinanced, repaid, or funded by a sale.

• Assets-held-for-sale or segment-reporting changes in the next 10-Q, which would show the process is real.

Sources

• Churchill Downs 8-K, Item 8.01 — the nine named properties (7/29/26)

• Churchill Downs Q2 2026 10-Q (filed 7/29/26)

• SEC XBRL — cover-page shares outstanding

• SEC XBRL — long-term debt, noncurrent

• stockanalysis — CHDN price and 52-week range

Previously: VOYA — the company says the shareholder meeting is fictitious. Tomorrow at 7 AM ET, a new one. Full archive →

On August 6, TOMS Capital Investment Management filed a preliminary non-management proxy statement at Voya Financial soliciting proxies for one item: a “No Confidence Referendum,” a resolution that shareholders “no longer continue to have confidence in the board of directors and management.” No directors are nominated; nothing else is on the ballot. And the filing says the meeting “is not being called pursuant to the special meeting procedures set forth in” Voya's charter or bylaws, “is not otherwise sanctioned by the Company, and no business of the Company is proposed to be transacted.” TOMS is not compelling a meeting and is not asking the board to call one. It is holding its own, and asking Voya's register to send proxies. On August 7 Voya called it “a fictitious shareholder meeting”, described the conduct as “manipulative and deceptive,” and said it is “seeking regulatory intervention.”

Why now? Thirteen days on, the meeting date, place and record date are still blank, and no definitive proxy has been filed. The newest filing of any kind on Voya's CIK is a passive 13G/A dated August 13. Meanwhile the stock closed August 18 at USD 100.16, within 4% of its 52-week high — the market is not pricing a governance crisis, and may be pricing a sale.

Numbers (at the August 18 close of USD 100.16):

• About USD 9.1 billion of market value on 90,596,349 shares (Q2 10-Q cover, July 31). Equity was USD 4.685 billion at June 30 — about USD 51.71 of book per share, so roughly 1.9x book.

• TOMS reports 4,055,700 shares, 4.47% of the class. Only 1,079,000 are actual common stock; the other 2,976,700 are exercisable call options. Options count toward beneficial ownership. They do not vote. The fund demanding a no-confidence vote can cast about 1.19% of one — roughly USD 108 million of stock.

• There is no quorum. Because the meeting is not called under the bylaws, the filing says Voya's quorum requirements “will not apply,” so turnout “will not affect whether the vote on the No Confidence Referendum is held.”

What kills it. Nearly everything, if you want a trade. The referendum is non-binding — the filing says so in capital letters — and the company has already said it will not recognize the meeting. Regulatory intervention could stop the solicitation outright. The stock sits near its high, so a sale may be largely in the price, and a retirement and benefits franchise is hard to sell: capital, ratings and multi-state approvals. This is interesting to dig in on as a governance question, not as a spread.

What to monitor

• A DEFN14A from TOMS with a real meeting date and record date — or its absence.

• Any SEC no-action request, comment letter or litigation from Voya's “regulatory intervention.”

• Whether TOMS exercises the calls and crosses 5% into a Schedule 13D.

• The buyback: cover-page shares fell about 70,000 between May 1 and July 31, after 2.1 million in the prior quarter.

Sources

• TOMS Capital PREN14A (8/6/26)

• Voya advisory to shareholders (8/7/26)

• TCIM DFAN14A (8/10/26)

• Voya EDGAR filing history

• stockanalysis — VOYA price

Built from public filings and existing write-ups in roughly the time it takes a reader to finish their first coffee. If the math, the framing, or the timing is wrong, that's the most useful kind of reply.

InMode is a Nasdaq-listed Israeli maker of aesthetic-medicine devices, and it has spent the summer being fought over. A group including CEO Moshe Mizrahy and investor Meir Shamir proposed USD 16.20 a share in cash on June 15. Steel Partners then bid USD 16.75 for the whole company on July 9 — its first offer for all of it, having previously only sought a majority stake. A special committee of three independent directors is weighing both. The stock closed Tuesday at USD 14.99, below each.

Why now?

Steel Partners did not just bid. On July 10 its affiliate went to the Haifa District Court asking it to order InMode and its directors to stop the committee from even considering the management proposal, arguing the directors were not independent enough to evaluate it. On August 10 the Court denied that in its entirety in favour of the company, and awarded the respondents costs. Separately, Mizrahy’s group extended its USD 16.20 proposal to expire September 15 — in a 13D amendment whose letter is dated July 8 but was filed August 5.

Numbers — at the August 18 close of USD 14.99, on 57,544,172 shares (AGM 6-K, 8/3):

• Market value about USD 865 million against USD 501.1 million of cash, securities and deposits at June 30 and no borrowings — total liabilities of USD 91 million are payables, contract liabilities and leases. Roughly USD 8.71 a share of cash; enterprise value near USD 363 million.

• So about USD 6.30 a share buys the operating business — one that did USD 95.6 million of Q2 revenue, dead flat versus Q2 2025, at a 75% gross margin, down from 80%. GAAP operating income was USD 12.3 million, and USD 7.4 million of the USD 17.1 million of net income was interest on the cash.

• The spread is 8.1% to the insider bid and 11.7% to Steel’s.

What kills it. A buyout priced by the buyers is a conflict, not a floor, and the committee can recommend nothing — a real outcome on a business with flat revenue and 500 basis points of gross-margin erosion. The court win is procedural: it lets the process continue, it does not deliver a deal. Israeli interested-party mechanics can require a disinterested-shareholder majority, and insiders hold a lot — Mizrahy 7.90%, CTO Michael Kreindel 5.11%. And the thing worth sitting with: Steel Partners has offered to buy the entire company and has not filed a Schedule 13D on it. Across InMode’s whole 2026 EDGAR history the only 13Ds are the two insiders’.

What to monitor

• A committee recommendation, or a 6-K disclosing a revised price from either side.

• Whether the USD 16.20 proposal is extended past September 15, or lapses.

• A Steel Partners Schedule 13D — its absence is the cheapest tell on how committed it is.

• Q3 revenue and gross margin: the cash cushion is the downside case, and it shrinks if the business does.

• Any appeal of the Haifa ruling.

If you cover aesthetic medical devices or contested take-privates professionally and have a sharper read, the reader form routes straight to the editor. The best pushback reshapes what gets written next.

Sources: Q2 results · Committee letter · Court ruling · 13D/A No. 5 · AGM results · Steel’s offer

Papa John’s (Nasdaq: PZZA) told analysts on its August 6 call that after roughly 18 months of exploring options — including a reported take-private bid from Irth Capital Management at USD 47 a share — it would stay independent and fund its transformation plan instead. The idea came off The Special Situation Report #226, and the framing there and everywhere else is the same: a failed process at a halved stock, with a motivated holder still on the register. The filings are narrower. Irth’s 13F filed August 14 is a one-line document — Papa John’s, 1,628,503 shares, USD 59.9 million, nothing else. Pull the other six it has filed since December 2024 and the number is 1,628,503 every time.

Why now? Against the 32,921,687 shares on the Q2 10-Q cover, that is 4.95% — parked just under the 5% line that forces a Schedule 13D and a written statement of intent within five business days. No 13D from Irth exists in EDGAR. So either the rest sits in swaps a 13F cannot see, or the “10%” being repeated is something else: Reuters reported in May that Irth had teamed with Papa John’s largest US franchisee, who owns about 10% of domestic restaurants — and described Irth itself as a top-five holder, not a 10% one.

At the August 17 close of USD 23.23:

• Market value is roughly USD 765 million. Add USD 727 million of debt less USD 28 million of cash from the Q2 release and the enterprise is about USD 1.5 billion — roughly 8x the midpoint of the USD 180–190 million of 2026 adjusted EBITDA guided in that same filed document.

• Irth’s USD 47 bid valued the equity near USD 1.55 billion. The whole enterprise today costs about what the fund offered for the shares alone.

• The board cut North America comparable-sales guidance to down 6–8% from down 2–4%, took adjusted EBITDA down from USD 200–210 million, and suspended a dividend that cost USD 30.9 million in the first half.

What kills it. Most of the above is the bear case in a bow tie. North America comps fell 8.3% in the quarter and the balance sheet carries a stockholders’ deficit. The 13F cuts both ways: swaps do not appear on one, so 4.95% is a floor on Irth’s exposure rather than a ceiling — but a fund sitting deliberately under 5% is one that has chosen not to run a public campaign, and it has not bought a share at these prices. And note what the company did not file: sweep the entire August 6 release and “strategic review,” “strategic alternatives” and “Irth” appear zero times. The conclusion everyone is trading on lives in call commentary, not in a filed document.

What to monitor

• A Schedule 13D from Irth — the event that turns this from a rumour into a situation.

• Irth’s next 13F in mid-November: the first read on whether 1,628,503 ever moves.

• Any 8-K that actually characterises the strategic process.

• Q3 comps against the fresh down 6–8% guide, and where the dividend money goes.

Yesterday’s note on DNOW is in the archive if you missed it — one idea a day, no exceptions.

Thesis. Andrew hosted Firebird Management on Yet Another Value Podcast on Friday to make the case for DNOW as a boring energy-and-industrial distributor that could double on 2029 numbers. What follows is the ten-minute overview for anyone who hasn't listened — built from the filings rather than the episode, because the filings are interesting by themselves. DNOW closed its all-stock combination with MRC Global on November 6, 2025, handing MRC holders 0.9489 DNOW shares apiece. The share count on the cover of the annual report went from 105,011,966 in October 2025 to 186,346,145 in February — call it 81 million shares of freshly printed currency. Since then it has run the other way: 180,785,891 on the cover of the second-quarter 10-Q, roughly 3% retired. Management bought USD 75 million of stock in the first half under a USD 160 million authorisation, and said plainly that this was "more shares purchased in these two quarters than in the previous 10 quarters combined." A team that issues a mountain of paper and then immediately starts buying it back is telling you something about what it thinks the paper is worth.

Why now? The second quarter was the first full quarter as a combined company, and the first real evidence that the US ERP conversion — the thing that had been wrecking the story — is turning. Revenue was USD 1,307 million, up 10% sequentially. Adjusted EBITDA was USD 60 million, up 54% sequentially. Operating cash flow was USD 133 million, a record for a second quarter. The catch is that the market noticed: the stock is up roughly 50% from its 52-week low and now sits a few percent below its high. This is not an undiscovered turn, it is a turn that is already partly in the price, and that is the honest version of why now.

Numbers

• At the August 14 close of USD 16.43, on the 180,785,891 shares from the 10-Q cover, the equity is roughly USD 3.0 billion. Add USD 474 million of long-term debt, take out USD 114 million of cash, and enterprise value is about USD 3.3 billion — just under 14x the second quarter's adjusted EBITDA annualised, which is not a cheap number.

• Net debt is USD 360 million, 1.7x on the company's own leverage math. The balance sheet is not the risk here.

• The USD 75 million of first-half buybacks is about 2.5% of the equity in six months, and the shares are retired rather than parked in treasury.

Risks — what kills it. The easy part of the re-rating has probably already happened; buying this a few percent off a 52-week high after a 50% run is a very different proposition from buying it at 11. The second quarter was still a GAAP net loss of USD 21 million, or USD 0.11 a share, against USD 21 million of adjusted net income — and the gap is integration cost that is real cash going out the door. The ERP conversion is not finished. And one thing worth flagging because it was a surprise: the synergy figures quoted everywhere — the USD 70 million three-year target, the raised first-year run rate — appear nowhere in the filed earnings release. They are call commentary. That does not make them wrong, but the number this thesis leans on is not a filed number.

What to monitor

• Share count on the next 10-Q cover. The buyback is the cleanest available read on what management actually thinks.

• Whether the USD 160 million authorisation gets refreshed or upsized once it is used up.

• Adjusted EBITDA margin holding in the mid-4s through a seasonally weaker quarter.

• Any filed disclosure that puts a synergy run-rate in a document rather than on a call.

• US midstream revenue, which the company said crossed USD 1 billion annualised for the first time this quarter.

Sources

• Yet Another Value Podcast #413 — DNOW with Firebird Management (8/14/26)

• DNOW Q2 2026 earnings release, 8-K Exhibit 99.1 (8/6/26)

• DNOW Q2 2026 Form 10-Q (8/6/26)

• SEC XBRL — shares outstanding on each cover page

• stockanalysis — DNOW price and 52-week range

Built from public filings and existing write-ups in roughly the time it takes a reader to finish their first coffee. If the math, the framing, or the timing is wrong, that's the most useful kind of reply.

Gentherm is combining with Modine's Performance Technologies business in a Reverse Morris Trust: Modine spins the unit and merges it into Gentherm, with Gentherm holders owning 60% of the result and Modine holders 40%. The mechanics have been public since the announcement, but until this week there was no date. On August 12 the S-4 went effective and Gentherm filed the definitive proxy/prospectus, which fixes the special meeting for September 10, 2026 and the record date at the close on July 31, 2026, with 30,739,019 shares entitled to vote.

Why now? There is finally a date, and reading the vote standards is where it gets interesting. Two proposals matter. The share issuance needs a majority of the votes cast. The charter amendment raising authorised shares - without which the issuance "will not be implemented" - needs a majority of the shares outstanding. Those are very different bars. Under the second, an abstention, a broker non-vote and a share nobody bothered to vote are all arithmetically identical to a vote against. On a 30.7-million-share company with a substantial retail register, that is the proposal to watch, not the headline one.

Numbers.

• At the August 14 close of USD 44.00 on 30,705,208 shares (Q2 10-Q cover, July 17), the equity is about USD 1.35 billion. The 52-week range is 27.00 to 48.35.

• The number of new shares is defined as fully diluted Gentherm shares multiplied by 40/60 - about two-thirds of the existing count, or roughly twenty million new shares. That is the dilution the charter amendment exists to permit.

• The break fee runs one way. Gentherm may owe Modine USD 45.0 million in specified circumstances; "Modine is not required to pay a termination fee under the Merger Agreement." That is about USD 1.46 a share, roughly 3% of the equity, payable by the side whose owners are being asked to vote.

• Target net working capital in the deal is set at USD 227,238,000, and the combined company is expected to be run by Gentherm's current CEO with Modine's Ron Hundzinski expected to stay as chair - control of the operating company sits on the Gentherm side of the table.

What kills it. The obvious thing: nothing has gone wrong. This is a consensual, board-approved transaction with no public dissent, no 13D, no opposing holder and no proxy adviser recommendation yet. Ranking it as a vote-risk idea is inference, and the tape does not support it either - the stock closed unchanged on August 12, the day the proxy landed, on 235,113 shares, the lightest volume of the month, then rose 4.0% and 2.2% over the next two sessions. That is a market treating the vote as a formality, and the market is usually right about that. RMTs are also slow and condition-heavy: an IRS ruling, the permanent SpinCo financing and regulatory clearances all sit behind the vote, and none of them is a date a reader can trade. And if it does close, holders own 60% of a larger, more cyclical auto-supplier - Modine is selling this business for a reason.

What to monitor.

• The ISS and Glass Lewis recommendations, which usually land roughly two weeks before a September 10 meeting.

• Any 13D or public holder objection between now and the vote. The record date has already passed, so the holder list is fixed.

• Retail participation rates - the only real risk to a majority-of-outstanding standard is apathy, not opposition.

• The permanent SpinCo financing replacing the bridge, and the IRS private letter ruling.

• Whether the adjournment proposal gets used on September 10. Adjourning to solicit more votes is what a company does when the outstanding-share bar is not being cleared.

Interesting to dig in on - not because anyone is fighting this, but because the deal is gated on a voting standard that fails to apathy, and there is now a date on it.

Sources: Definitive proxy statement/prospectus, Form 424B3 (8/12/26) · Gentherm EDGAR filing index · SEC XBRL share count, Q2 10-Q cover · THRM price history

If you cover auto suppliers or thermal management professionally and have a sharper read, the reader form routes straight to the editor. The best pushback reshapes what gets written next.

On August 3, Tarun Lal told the Dave & Buster’s board he was retiring as CEO effective that same day, “in order to spend more time with his family in India.” He had been announced as CEO on July 15, 2025. Seven weeks before he left, alongside the first-quarter numbers, he said he was “highly confident in our ability to drive positive comps for the remainder of the year.” CFO Darin Harper took the job, the treasurer and head of IR became interim CFO, and the board rearranged itself the next day — James Chambers from vice chair to chair, Kevin Sheehan from chair into a lead independent director role that had been sitting empty.

The departure is not the interesting part. What the board paid to replace him is.

Why now? The grants have landed and they are now on file. Harper’s Form 4, filed August 13 for an August 10 grant date, shows 228,426 options struck at USD 9.85, 228,426 same-store-sales performance shares and 203,046 RSUs — roughly 1.9% of the shares outstanding to one person. The options become earned only if the 60-day trailing VWAP reaches twice the strike, USD 19.70, within three years. And USD 9.85 was the August 10 close, which was the lowest close since the CEO change was announced. The stock has not closed below it since.

Numbers.

• At the August 14 close of USD 10.19, the equity is about USD 355 million against an enterprise value near USD 3.9 billion — USD 19.6 million of cash against USD 3.56 billion of debt and capitalised leases (source). The equity is under a tenth of the enterprise, so moving the stock to USD 19.70 takes less than a 10% increase in enterprise value. The hurdle is a good deal less heroic than the word “doubling” suggests.

• The performance shares vest on same-store sales growth of at least 2%, measured independently across the back half of fiscal 2026, fiscal 2027 and fiscal 2028. Comps in the quarter ended May 5 were negative 5.4%, on revenue of USD 559.2 million (down 1.5%) and adjusted EBITDA of USD 123.2 million against USD 136.1 million a year earlier.

• Lal’s separation pays him USD 85,833.33 a month as an adviser through January 31, 2028, plus a pro-rata bonus and option acceleration — roughly USD 1.5 million of consulting fees for a voluntary retirement.

What kills it. Reading a compensation committee’s hurdles as a forecast is a weak form of analysis, and it is the main thing wrong with this idea — boards set 2x hurdles they miss all the time, and a strike price is not a plan for fixing comps. The leverage cuts the other way with the same violence: if enterprise value falls a tenth, the equity roughly halves, and this is a business with a 0.81 Altman Z-score, a trailing net loss of USD 64.7 million and interest coverage under 1x. Two CEOs in two years at a levered casual-dining operator is usually a symptom rather than a setup, and promoting the sitting CFO is continuity, not change. Roughly 28% of shares outstanding are sold short, so the tape will be violent in both directions.

What to monitor.

• Second-quarter results on September 14, after the close — the first comp print under Harper, and the first read on whether +2% is reachable from −5.4%.

• The next 10-Q, where the full Harper employment agreement, offer letter and Lal separation agreement get filed.

• Whether a permanent CFO is named; the interim CFO’s own grant partially accelerates when one is.

• Hill Path’s next filing, and whether the July 2022 cooperation agreement among the company, Hill Path and James Chambers changes now that Chambers is chair.

• The 60-day trailing VWAP against USD 19.70 — the only number here that pays anyone.

Interesting to dig in on. Not because an incentive is a thesis, but because the board just put in a filing the exact price at which it thinks this equity gets interesting.

Sources: Form 8-K, CEO transition (filed 8/4/26) · Harper Form 4 (filed 8/13/26) · Q1 fiscal 2026 results (6/15/26) · PLAY price history · PLAY statistics

Yesterday: BVS — the sale process is live, and the pop is already gone. Tomorrow at 7 AM ET, a new one. Full archive →

Thesis. Bioventus is a Durham-based orthopedics business — hyaluronic acid injections, ultrasonic surgical tools, and the EXOGEN bone stimulator — that spent most of the last two years as a levered turnaround story. It has since paid down a lot of debt and, on August 5, disclosed alongside second-quarter results that it had received an unsolicited acquisition proposal and multiple other expressions of interest, and that a committee of independent directors is now evaluating alternatives including a sale, with Evercore advising and Latham & Watkins as counsel. The sequencing is what makes it interesting rather than routine: a buyer showed up first, and the process is the board's answer to that, not a banker sent out to go find someone.

Why now? Because the price action has undone itself. Bioventus closed at 13.42 on August 4. On August 5 it opened lower, ran to an intraday 15.893 — which is the 52-week high — and closed at 15.26, up 13.7% on 2.5 million shares. The very next session it fell 8.4%, and it has drifted since: 14.125, 13.96, 13.85, and 13.915 on August 12. You are now paying only modestly more than the last uninformed price for a company that has a bid on the table and a banker running a process. Either the market has decided nothing comes of this, or it has stopped paying attention. Neither is obviously right.

The numbers, all at the August 12 close of USD 13.915 and off the second-quarter release:

• Class A and Class B together are 83,998,555 shares as of June 27, so just under USD 1.2 billion of equity value. Add net debt of USD 219 million (USD 248 million drawn against USD 29 million of cash) and enterprise value is roughly USD 1.4 billion, against last-twelve-months adjusted EBITDA of about USD 122 million.

• Net leverage is therefore around 1.8 times — a long way from where this business was. Bioventus paid down USD 45.8 million of term debt in the first half, USD 20 million of it a discretionary prepayment, and interest expense fell from USD 7.5 million to USD 4.1 million year over year.

• Second-quarter revenue was USD 153.2 million, up 3.8%, but the growth is one segment: Pain Treatments up 11.5%, Surgical Solutions down 4.5%, Restorative Therapies down 2.4%. Full-year guidance of USD 600 to 610 million in sales and USD 0.75 to 0.79 of adjusted earnings per share was reaffirmed.

What kills it. Start with the headline everyone quoted. GAAP earnings of USD 0.47 per share against USD 0.11 a year ago looks like a business inflecting, and it mostly is not — USD 24.6 million of it is the release of a deferred tax valuation allowance. Adjusted earnings per share went from USD 0.21 to USD 0.22, up 5%. The business is fine; it is not transformed.

Then the process itself. The company explicitly set no timetable and said it does not intend to disclose anything further unless and until a transaction is approved, so there is no date to key off and no obligation to tell you it fizzled. Boards that disclose an approach very often end up executing the standalone plan. The stock had also already run from 11.80 on July 24 to 13.42 on August 4 before the announcement, so some of this was in the price before it was news. And the shrinking segment is the one with a live regulatory question: the FDA's reclassification of non-invasive bone growth stimulators sits directly on EXOGEN, and Restorative is declining on Medicare customer mix.

What to monitor.

• Any 8-K, SC 14D9, or definitive agreement. The company has said it will go quiet until there is one, so a filing is the whole signal.

• A 13D or 13G from an event-driven holder, which would say someone else thinks this finishes.

• Third-quarter results in early November, and whether the Surgical Solutions revenue management attributed to timing of Ultrasonics capital placements into the second half actually shows up.

• Restorative Therapies, and any further FDA action on bone growth stimulator classification.

• The term loan balance. More discretionary prepayment is a board acting like it has time.

Sources: Bioventus Form 8-K, August 5, 2026 · second-quarter 2026 earnings release · Latham & Watkins · price and daily history via stockanalysis

Built from public filings and existing write-ups in roughly the time it takes a reader to finish their first coffee. If the math, the framing, or the timing is wrong, that's the most useful kind of reply.

BlackRock TCP Capital is an externally managed BDC that has spent two years shrinking and marking down: net asset value per share went USD 7.07 at year-end 2025, to USD 6.72 in March, to USD 6.58 in June. On August 4 it agreed to sell 95% of a vehicle holding about USD 523 million of investments across 78 portfolio companies to funds managed by Pantheon, keeping a 5% strip and, on average, about a third of each underlying position. It disclosed the deal on August 6 with second-quarter results, and in the same release said the board had engaged KBW to consider strategic alternatives including repurchases, strategic combinations, or "an orderly realization of portfolio assets." A board that puts orderly realization in a press release is telling you liquidation is on the menu.

Why now?

The direction of the market's reaction is easy to get wrong here. TCPC rose 11.4% on August 6 on 2.9 million shares, then another 5.4% on August 7 to USD 4.11, then gave back about 5% over two sessions on lighter volume. This is not a hated post-announcement stock; it already re-rated, and the red days look like the pop deflating rather than news. What has not re-rated is the gap to book. The review has no timetable, the repurchase plan runs only to April 30, 2027, and the first quarter showing what this company earns at its new leverage does not print until November.

The numbers

• The discount survives the haircut. June 30 NAV was USD 6.58 on 83,902,775 shares; subtract the disclosed USD 0.68 and pro forma NAV is roughly USD 5.90. The August 11 close of USD 3.90 is about two-thirds of that, and more than 40% below the 52-week high of USD 7.28. Net leverage falls from 1.38 times to roughly 0.4 times, and under 0.3 after an announced paydown.

• The buyback is 94% unused. The board re-approved a USD 50 million repurchase plan on April 29, 2026, running to April 30, 2027. In the first six months of the year TCPC bought 661,803 shares for USD 2.87 million, at an average of USD 4.34 — above today's price. That leaves roughly USD 47 million unspent, enough to retire more than an eighth of the shares outstanding here.

• The dividend is covered, at the old leverage. Net investment income was USD 18.1 million, or USD 0.22 per share, against the USD 0.17 regular dividend — USD 0.68 annualized, roughly a 17% yield. But that USD 0.22 came off a book levered 1.38 times, funded at a 6.03% blended cost against an 11.2% debt-portfolio yield. Removing 48% of the debt portfolio removes most of that spread. The third-quarter dividend is already declared, payable September 30; the fourth quarter is the open question.

What kills it

The earnings hole above, and the marks underneath it. Non-accruals were 1.6% of the portfolio at fair value on June 30 but 7.4% at cost, across thirteen portfolio companies — an orderly realization of a marked-down loan book realizes the marks, not the book. The framing deserves a squint too: management calls the sale "a substantial premium relative to the value implied by the Company's current share price," which compares it to the stock rather than to carrying value, against which it is a 10.4% hit. And the party running the review is BlackRock, paid on assets, weighing options that shrink its own fee base — though in fairness the advisor is managing the continuation vehicle's assets without compensation, which is not what a fee-maximizer does.

What to monitor

• Any use of the USD 47 million authorization — the cleanest single signal that the review is real

• Third-quarter results, the first at roughly 0.4x leverage, and whether the USD 0.17 dividend holds into Q4

• Non-accruals at cost, currently 7.4%, and whether that falls because loans cure or because they get sold

• Anything actually from KBW: a combination, a tender, or a plan of liquidation

• Closing of the Pantheon transaction and the realized NAV hit against the 10.4% estimate

Sources: SEC 8-K exhibit — Q2 2026 results, USD 523M portfolio sale, KBW engaged (8/6/26) · Businesswire — Q2 results and the portfolio sale (8/6/26) · SEC — Q2 2026 Form 10-Q · stockanalysis.com — TCPC quote and price history

If you cover BDCs or private-credit secondaries professionally and have a sharper read on what a 0.4x-levered TCPC actually earns, the reader form routes straight to the editor. The best pushback reshapes what gets written next.

Ethan Allen is a vertically integrated furniture retailer — 171 design centers, about 75% of its custom furniture built in its own North American plants — whose revenue has roughly halved since 2007, to USD 579.5 million in the fiscal year ended June 30. On August 5, DGB Investment filed a 13D and nominated a six-person slate, including former senior executives of Wayfair, eBay, Neiman Marcus and Barclays. Bergeron bought VeriFone from HP for USD 50 million in 2001, and ran a 2020 proxy contest at USA Technologies that turned over the entire board. Credit to The Special Situation Report's activism roundup for surfacing it.

The part the summaries miss is the size of the ask. Ethan Allen’s board has six seats, all elected annually — the 2025 proxy put up six nominees — so a six-person slate is the entire board. Neither side is pretending otherwise. Kathwari went on Bloomberg Television on August 7 and the company filed the transcript, in which Bergeron calls the business a melting ice cube and says the campaign’s purpose is to recruit a new CEO, and Kathwari, 82, notes that Bergeron is 66 and “looks 95.”

Why now?

No meeting date is set, but the calendar is knowable. Ethan Allen has held its annual meeting in the first half of November four years running — November 5 last year, off a mid-September record date and a proxy filed September 26 — so the definitive proxy should land inside about six weeks.

The numbers

• Cheap and unlevered. At the August 10 close of USD 23.51 on 25,446,339 shares, the market cap is about USD 600 million against USD 187.5 million of cash and investments and no outstanding debt — cash is nearly a third of the cap, and the resulting enterprise value is roughly 9 times fiscal 2026 adjusted operating income of about USD 47 million. The release nets out debt but not the operating leases behind 141 company-operated design centers.

• The dividend is not covered by free cash flow. Fiscal 2026 threw off USD 52.5 million of operating cash flow against USD 11.0 million of capex, and the company paid USD 46.3 million of dividends. The board just declared another USD 0.25 special plus the USD 0.39 regular, both payable August 26; the regular rate alone is roughly a 6.6% yield at the August 10 close.

• The order book is the actual complaint. Fourth-quarter written orders fell 11.9% in wholesale and 10.8% in retail; for the full year, wholesale was down 11.2% and retail 6.1%. Adjusted diluted EPS fell to USD 1.61 from USD 2.04.

What kills it

The vote math, and there is an uncomfortably close precedent. In 2015 Sandell Asset Management owned about 5.5% of Ethan Allen, nominated six of seven directors, and lost decisively, with ISS, Glass Lewis and Egan-Jones all backing the board. Bergeron starts from less: his 1,275,000 shares are 5.0%, but 275,000 are call options he cannot vote until exercised, so the real block is 3.9%. Kathwari personally holds 9.4%. That hands the outcome to BlackRock (13.5%), Dimensional (7.0%) and Vanguard (6.3%) — index and quant money that mostly follows the proxy advisers, who sided with this board last time. No second holder has surfaced publicly in the week since the filing.

What to monitor

• The definitive proxy and record date, expected late September on the four-year pattern

• Whether the by-laws drop to plurality voting in a contested election, which changes the arithmetic entirely

• A 13D/A from Bergeron adding shares or exercising the options, or any second holder filing

• ISS and Glass Lewis recommendations, historically the whole ballgame at this company

• First-quarter fiscal 2027 written orders, the series the incumbent defence depends on

Sources: SEC Schedule 13D — DGB Investment, six-person slate (8/5/26) · Ethan Allen fiscal 2026 results and dividends (7/29/26) · Company confirms receipt of the nominations (8/5/26) · Kathwari on Bloomberg Television, transcript filed (8/7/26) · 2025 proxy statement · Institutional Investor — Sandell loses the 2015 Ethan Allen proxy fight · The Special Situation Report #226 (8/9/26) · stockanalysis.com — ETD quote

Yesterday: PLTK — the studio Tencent reportedly wants is also the bill Playtika owes. Tomorrow at 7 AM ET, a new one. Full archive →